Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword
Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/8/1225 |
| _version_ | 1797409337638912000 |
|---|---|
| author | Mengwan Wu Ying Shi Luyi Zhu Luoyi Chen Xinchen Zhao Chuan Xu |
| author_facet | Mengwan Wu Ying Shi Luyi Zhu Luoyi Chen Xinchen Zhao Chuan Xu |
| author_sort | Mengwan Wu |
| collection | DOAJ |
| description | Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain fatigued in GBM patients. Emerging evidence has shown that GBM-associated macrophages (GAMs), comprising brain-resident microglia and bone marrow-derived macrophages, act critically in boosting tumor progression, altering drug resistance, and establishing an immunosuppressive environment. Based on its crucial role, evaluations of the safety and efficacy of GAM-targeted therapy are ongoing, with promising (pre)clinical evidence updated. In this review, we summarized updated literature related to GAM nature, the interplay between GAMs and GBM cells, and GAM-targeted therapeutic strategies. |
| first_indexed | 2024-03-09T04:11:44Z |
| format | Article |
| id | doaj.art-78c54351e2f64304a5fcff2dd4d89027 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T04:11:44Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-78c54351e2f64304a5fcff2dd4d890272023-12-03T13:58:55ZengMDPI AGLife2075-17292022-08-01128122510.3390/life12081225Macrophages in Glioblastoma Development and Therapy: A Double-Edged SwordMengwan Wu0Ying Shi1Luyi Zhu2Luoyi Chen3Xinchen Zhao4Chuan Xu5Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, ChinaGlioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain fatigued in GBM patients. Emerging evidence has shown that GBM-associated macrophages (GAMs), comprising brain-resident microglia and bone marrow-derived macrophages, act critically in boosting tumor progression, altering drug resistance, and establishing an immunosuppressive environment. Based on its crucial role, evaluations of the safety and efficacy of GAM-targeted therapy are ongoing, with promising (pre)clinical evidence updated. In this review, we summarized updated literature related to GAM nature, the interplay between GAMs and GBM cells, and GAM-targeted therapeutic strategies.https://www.mdpi.com/2075-1729/12/8/1225glioblastomamacrophagemicrogliaimmunotherapytargeted therapy |
| spellingShingle | Mengwan Wu Ying Shi Luyi Zhu Luoyi Chen Xinchen Zhao Chuan Xu Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword Life glioblastoma macrophage microglia immunotherapy targeted therapy |
| title | Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword |
| title_full | Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword |
| title_fullStr | Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword |
| title_full_unstemmed | Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword |
| title_short | Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword |
| title_sort | macrophages in glioblastoma development and therapy a double edged sword |
| topic | glioblastoma macrophage microglia immunotherapy targeted therapy |
| url | https://www.mdpi.com/2075-1729/12/8/1225 |
| work_keys_str_mv | AT mengwanwu macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword AT yingshi macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword AT luyizhu macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword AT luoyichen macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword AT xinchenzhao macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword AT chuanxu macrophagesinglioblastomadevelopmentandtherapyadoubleedgedsword |